$358.41
Insights on Argenx Se
Revenue is up for the last 8 quarters, 23.41M → 407.43M (in $), with an average increase of 30.2% per quarter
Netprofit is down for the last 2 quarters, -72.64M → -99.31M (in $), with an average decrease of 36.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 49.2%
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 215.1%
0.09%
Downside
Day's Volatility :2.49%
Upside
2.4%
8.56%
Downside
52 Weeks Volatility :40.49%
Upside
34.92%
Period | Argenx Se | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 0.11% | -0.7% | 0.0% |
6 Months | -25.32% | 6.6% | 0.0% |
1 Year | -2.54% | 3.7% | -1.5% |
3 Years | 33.26% | 14.0% | -21.8% |
Market Capitalization | 22.6B |
Book Value | $69.22 |
Earnings Per Share (EPS) | -5.16 |
PEG Ratio | 0.0 |
Wall Street Target Price | 478.76 |
Profit Margin | -23.26% |
Operating Margin TTM | -32.75% |
Return On Assets TTM | -6.85% |
Return On Equity TTM | -8.54% |
Revenue TTM | 1.3B |
Revenue Per Share TTM | 0.89 |
Quarterly Revenue Growth YOY | 134.9% |
Gross Profit TTM | -251.8M |
EBITDA | -316.8M |
Diluted Eps TTM | -5.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.57 |
EPS Estimate Next Year | 4.05 |
EPS Estimate Current Quarter | -1.7 |
EPS Estimate Next Quarter | -0.86 |
What analysts predicted
Upside of 33.58%
Sell
Neutral
Buy
Argenx Se is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Argenx Se | 1.29% | -25.32% | -2.54% | 33.26% | 209.55% |
Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Argenx Se | NA | NA | 0.0 | -2.57 | -0.09 | -0.07 | NA | 69.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Argenx Se | Buy | $22.6B | 209.55% | NA | -23.26% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
FMR Inc
T. Rowe Price Associates, Inc.
Artisan Partners Limited Partnership
Capital World Investors
HHG PLC
venBio Select Advisor LLC
Argenx Se’s price-to-earnings ratio stands at None
Read MoreArgenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
Organization | Argenx Se |
Employees | 1148 |
CEO | Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc. |
Industry | Health Technology |
American International Group, Inc.
$358.41
-2.13%
Williams-sonoma Inc.
$358.41
-2.13%
Ishares Msci Emr Mrk Ex Chna
$358.41
-2.13%
Nvr, Inc.
$358.41
-2.13%
Paychex, Inc.
$358.41
-2.13%
Industrial Select Sector Spdr
$358.41
-2.13%
Genuine Parts Company
$358.41
-2.13%
Public Storage
$358.41
-2.13%
Microstrategy Inc.
$358.41
-2.13%